{
    "cancer_info": {
        "cancer_name": "Small Cell Lung Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Contrast-enhanced CT of chest/abdomen/pelvis",
            "Brain MRI (preferred) or contrast-enhanced CT",
            "FDG-PET/CT (skull base to mid-thigh) for disease extent clarification",
            "Biopsy with histopathology (H&E) and immunohistochemistry (IHC)",
            "IHC markers: TTF-1, INSM1, chromogranin, synaptophysin, CD56, Ki-67",
            "Molecular profiling for relapsed ES-SCLC with atypical features",
            "CBC, electrolytes, LFTs, BUN, creatinine",
            "LDH testing",
            "Hyponatremia screening",
            "Paraneoplastic syndrome markers (anti-Hu antibodies)",
            "Bone scan or MRI if PET-CT equivocal",
            "Thoracentesis for pleural effusion",
            "Thoracoscopy if thoracentesis inconclusive",
            "Mediastinal staging (EBUS/EUS/mediastinoscopy) for surgical candidates",
            "Pulmonary Function Tests (PFTs) for surgery/RT candidates"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Limited Stage (LS-SCLC): Stages I-IIIC (T1-T4, N0-N3, M0)",
            "risk_group": "Surgical Candidates: T1-2 N0 M0",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Stage I-IIA (T1-2 N0 M0)",
                    "plan_name": "Surgical Resection",
                    "plan_details": "Lobectomy + mediastinal lymph node dissection",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                },
                {
                    "treatment_line": "Adjuvant Therapy",
                    "patient_subgroup": "N0",
                    "plan_name": "Systemic Therapy",
                    "plan_details": "Chemotherapy alone post-surgery",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Adjuvant Therapy",
                    "patient_subgroup": "N1/N2",
                    "plan_name": "Systemic Therapy ± Mediastinal RT",
                    "plan_details": "Chemotherapy with optional radiation therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Limited Stage (LS-SCLC): Stages I-IIIC (T1-T4, N0-N3, M0)",
            "risk_group": "Non-Surgical: Medically inoperable or Stage IIB-IIIC",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Concurrent Chemoradiation",
                    "plan_details": "Cisplatin/etoposide + thoracic RT (Accelerated: 45 Gy BID over 3 weeks; Conventional: 60-70 Gy daily over 6-7 weeks)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Limited Stage (LS-SCLC): Stages I-IIIC (T1-T4, N0-N3, M0)",
            "risk_group": "Complete responders after primary treatment",
            "treatment_plans": [
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Pathologic stage I (T1-2a N0 M0)",
                    "plan_name": "MRI Surveillance",
                    "plan_details": "Omit PCI due to low brain metastasis risk",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Non-surgical patients",
                    "plan_name": "Durvalumab",
                    "plan_details": "1500 mg q28d until progression/max 24 months",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Complete responders",
                    "plan_name": "Prophylactic Cranial Irradiation (PCI)",
                    "plan_details": "25 Gy in 10 fractions (with hippocampal avoidance)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Extensive Stage (ES-SCLC): Any T/N with M1 disease",
            "risk_group": "All",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "PD-L1+",
                    "plan_name": "Chemoimmunotherapy",
                    "plan_details": "Carboplatin (AUC 5) + etoposide + atezolizumab → maintenance atezolizumab (1200 mg q3w)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "PD-L1+",
                    "plan_name": "Chemoimmunotherapy",
                    "plan_details": "Carboplatin (AUC 5-6) + etoposide + durvalumab → maintenance durvalumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Platinum-etoposide",
                    "plan_details": "Cisplatin/carboplatin + etoposide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Consolidation",
                    "patient_subgroup": "Responders with low-bulk disease",
                    "plan_name": "Thoracic Radiotherapy",
                    "plan_details": "30 Gy in 10 fractions",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "CTFI ≥6 months",
            "treatment_plans": [
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "All",
                    "plan_name": "Platinum rechallenge or Lurbinectedin",
                    "plan_details": "Platinum doublet rechallenge or Lurbinectedin (3.2 mg/m² q3w)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "CTFI <6 months",
            "treatment_plans": [
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "All",
                    "plan_name": "Topotecan or Tarlatamab",
                    "plan_details": "Topotecan (IV/oral) or Tarlatamab (10 mg IV, anti-DLL3)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "Neuroendocrine markers (INSM1, chromogranin, synaptophysin, CD56) confirm SCLC diagnosis (>95% sensitivity)",
            "POU2F3 identifies neuroendocrine-low SCLC subtype",
            "TTF-1 distinguishes SCLC from NSCLC (positive in 85-90% SCLC)",
            "Ki-67 (>50%) supports SCLC diagnosis",
            "PD-L1 expression guides first-line immunotherapy in ES-SCLC",
            "DLL3 expression (85-94% of SCLC) enables targeted therapy with tarlatamab",
            "MGMT methylation predicts temozolomide response in relapsed disease"
        ]
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：小细胞肺癌.txt"
}